Seroprevalence of chlamydia pneumoniae antibodies in stroke in young

Canadian Journal of Neurological Sciences

Volumn 36, Issue 6, 2009, Pages 725-730

  Bandaru, V C S Srinivasarao ^a   Boddu, D Babu ^a   Laxmi, V ^b   Neeraja, M ^b   Kaul, S ^a,b  

^a Department of Neurology ^*  (India)

^b NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ACUTE DISEASE; ADOLESCENT; ADULT; ALCOHOLISM; ANTIBODY DETECTION; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CASE CONTROL STUDY; CHILD; CHLAMYDOPHILA PNEUMONIAE; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEROPREVALENCE; STROKE; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 70350303924     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100008337     Document Type: Article

References (37)

1. Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986;315(3):161-168
2. Campbell LA, Kuo CC, Grayston JT. Chlamydia pneumoniae and cardiovascular disease. Emerging Infect Dis. 1998;4(4):571-579
3. Brassard P, Bourgault C, Brophy J, Suissa S.Antibiotics in primary prevention of stroke in the elderly. Stroke. 2003;34(9):e163-e167.
4. Zeman K, Pospisil L, Canderle J, Stroblova H, Leypold J, Gregor Z, et al. Direct and indirect evidence of Chlamydia pneumoniae in patients with significant steonsis of A. carotis of atherosclerotic origin. Script Medica(Brno). 2004;77(3):173-180
5. Camm AJ, Fox KM. Chlamydia pneumoniae (and other infective agents) in atherosclerosis and acute coronary syndromes. Eur Heart J. 2000;21(13):1046-1051
6. Shor A, Phillips JI. Chlamydia pneumoniae and arthrosclerosis. JAMA. 1999;282(21):2071-2073
7. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH. Serological evidence of an association of novel Chlamydia TWAR with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2(8618):983-986
8. Elkind MSV, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumoniae and risk of first ischemic stroke: The Northern Manhattan Stroke Study. Stroke. 2000;31(7):1521-1525
9. Danesh J, Whnicup P, Lewington S, WalkerM, Lennon L, Thomson A, et al. Chlamydia pneumoniae IgA titers and coronary heart disease. Eur Heart J. 2002;23(5):371-375
10. Melnick SL, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang SP, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am J Med. 1993;95 (5):499-504.
11. Grau AJ, Buggle F, Ziegler C, SchwarzW, Meuser J, Tasman AT, et al. Association between acute cerebrovascular ischemia and chronic and recurrent infection. Stroke. 1997;28(9):1724-1729
12. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schorll M. Stroke incidence, case fatality and mortality on the WHO MONICA project. World Health Organization Monitoring Trends and Determinates in Cardiovascular Disease. Stroke. 1995;26(3):361-367
13. Chobanian AV, Bakris GL, Balack HR, CushmanWC, Green LA Jr, Izzo JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42(6):1206-1252
14. Radhakrishnamurty B. Diabetes mellitus: In: Heart Disease, Radhakrishnamurty B, editor. Columbus, GA: Quill Publication; 2003. p. 31-37
15. Falck G, Gnarpe J, Hansson LO, Svardsudd K, Gnarpe H. Comparison of individuals with and without specific IgA antibodies to Chlamydia pneumoniae: respiratory morbidity and the metabolic syndrome. Chest. 2002;122(5):1587-1593
16. Saponink G, Caplan LR, Gonzalez LA, Baird A, Dashe J, Luraschi A, et al. Differences in stroke subtypes among natives and Caucasians in Boston and Buenos Aires. Stroke. 2000;31(10): 2385-2389
17. Ueland PM, Refsum H, Stabler SP, Malinow R, Andersson A, Allen RH. Total homocysteine in plasma or serum; methods and clinical application. Clin Chemist. 1993;39(9):1764-1779
18. Radhakrishnamurty B. Blood Lipids. In: Heart disease. Radhakrishnamurty B, editor. Columbus GA: Quill Publication; 2003. p. 18-27.
19. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtypes of acute ischemic stroke. Stroke. 1993;24(1):35-41.
20. Anzini A, Cassone A, Rasura M, Ciervo A, Beccia M, Di Lisi F, et al. Chlamydia pneumoniae infection in young stroke patients: a case control study. Eur J Neurol. 2004;11(5):321-327
21. Voorend M, Faber CG, van der Ven AJAM, Kessels F, Bruggeman CA, Lodder J. Chlamydia pneumoniae is a likely risk factor for ischemic stroke in young patients. J Stroke Cerbrovasc Dis. 2004;13(2):85-91.
22. Wimmer MLJ, Sandmann-Strupp R, Saikku P, Haberl RL. Association of Chlamydia infection with Cerebrovascular Disease. Stroke. 1996;27(12):2207-2210
23. Njamnshi AK, Blackett KN, Mbagbaw JN, Gumedze F, Gupta S, Wiysonge CS. Chronic Chlamydia pneumoniae infection and stroke in Cameroon. Stroke. 2006;37(3);796-799.
24. Piechowski-Jozwiak B, Mickielewicz A, Gaciong Z, Berent H, Kwiecinski H. Elevated levels of anti-Chlamydia pneumoniae IgA and IgG antibodies in young adults with ischemic stroke. Acta Neurologica Scandinavica. 2007;116(3):144-149
25. Dowell SF, Boman J, Carlone GM, Fields BS, Guarner J, Hammerschlag MR, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Center for Diseases (Canada). Clin infect Dis. 2001;33(4):492-503.
26. Essig A, Simnaher U, Susa M, Marre R. Analysis of the humoral immune response to Chlamydia pneumoniae by immunoblotting and immnoprecipitation. Clin Diagn Lab Immunol. 1999;6(6):819-825
27. Larsen MM, Moern B, Fuller A, Andersen PL, Ostergaard LJ. Chlamydia pneumoniae and cardiovascular disease. Med J Aust. 2002;177(10):558-562
28. Hertzen LV, Isoaho R, Kivela SR, Saikku P. Finnish study finds significant association between raised IgG, but not IgA, titres and mortality. BMJ. 1999;319(7224):1575-1576 (Editorial letter).
29. Agrawal A, Chander Y, Nagendra A. Serological evidence of chronic Chlamydia pneumoniae infection in coronary artery disease. Med J Armed Forces India. 2007;63:229-232
30. Bandaru VCSS, Laxmi V, Neeraja M, Alladi S, Meena AK, Borgohain R, et al Chlamydia pneumoniae antibodies in various subtypes of ischemic stroke in Indian patients. J Neurol Sci. 2008;272(1-2):115-122
31. Davidson M, Kuo CC, Middaugh JP, Campbell LA, Wang SP, Newman III WP, et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation. 1998;98(7):628-633
32. Wang SP. The Microimmunofluorescence test for Chlamydia pneumoniae infection: technique and interpretation. J Infect Dis. 2000:181 Suppl 3:S421-S425.
33. Kol A, Bourcier T, Litchman AH, Libby P. Chlamydia and human heart shock protein 60s active human vascular endothelium smooth muscles cells, and macrophages. J Clin Invest. 1999; 103(4):571-577
34. Fryer RH, Woods ML, Rogers GM. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med. 1997;45(4):168-174
35. Young B, Glesson M, Cripps AW. C-reactive protein: a critical review. Pathol. 1991;23(2):118-124
36. Ridker PM. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation. 1998;97(17):1671-1674
37. Byrne GI, Kalayoglu MV. Chlamydia pneumoniae and atherosclerosis: links to the disease process. Am Heart J. 1999; 138(5 Pt 2):S448-S490.